NPPA slaps Rs 300-crore penalty on Novartis for overcharging
Drug major Novartis has been slapped with a Rs 300-crore penalty by drug regulator NPPA for overcharging consumers on sale of Voveran, its best-selling painkiller medicine.
Oct 13, 2014, 23:00 PM IST